Statins and Dementia: Continue Therapy
Continue statin therapy in older adults despite concerns about dementia—current evidence demonstrates no causal link between statins and cognitive decline, while showing potential neuroprotective benefits and clear cardiovascular mortality reduction.
The Evidence Against Cognitive Harm
The concern that statins cause dementia or cognitive decline is not supported by high-quality evidence. A comprehensive 2026 narrative review examining RCTs, observational studies, meta-analyses, and Mendelian randomization studies involving over 100,000 individuals found no causal effect of statins on dementia or neurodegenerative diseases 1.
The largest meta-analysis to date (2025), including 55 observational studies with over 7 million patients, actually demonstrated the opposite: statin use significantly reduced dementia risk (HR 0.86; 95% CI: 0.82-0.91), with even greater reductions for Alzheimer's disease specifically (HR 0.82; 95% CI: 0.74-0.90) 2.
A 2021 prospective study of 18,846 adults ≥65 years followed for 4.7 years found no association between statin use and incident dementia, mild cognitive impairment, or declines in any cognitive domain 3. This held true regardless of whether statins were lipophilic or hydrophilic.
Mortality Benefits Persist in Dementia
Even in nursing home residents with established dementia, statins provide substantial survival benefit. A 2024 retrospective cohort study of 282,693 nursing home residents found that statin use reduced all-cause mortality by 20% in those with dementia (HR 0.80; 95% CI: 0.78-0.82) and by 27% in those without dementia (HR 0.73; 95% CI: 0.71-0.76) 4. These benefits persisted across all subgroups including those without atherosclerotic cardiovascular disease.
When to Consider Discontinuation
Guidelines provide limited specific recommendations for statin discontinuation in older adults. A 2020 systematic review of 18 international cardiovascular prevention guidelines found that only three guidelines suggested considering discontinuation in patients with poor health status—none provided age-specific cutoffs 5.
Consider discontinuation only when:
- Life expectancy is severely limited (< 6-12 months) due to terminal illness
- Severe frailty with complete functional dependence
- Patient goals shift entirely away from longevity toward comfort care
- Documented statin intolerance with muscle symptoms or other adverse effects
Do NOT discontinue based on:
- Age alone (even >85 years)
- Presence of dementia diagnosis
- Concerns about cognitive effects
- Primary prevention status in otherwise healthy older adults
The Cardiovascular Priority
For adults aged 75-85 years who are reasonably healthy, benefits of statins generally outweigh risks, especially in secondary prevention 5. The 2018 JACC guideline emphasizes that focusing solely on mortality in the elderly is "no longer tenable"—the majority of cardiovascular events in older adults are nonfatal, and preventing these morbid events preserves quality of life 6.
Important Caveats
- Polypharmacy matters: Monitor for drug-drug interactions, particularly with CYP3A4-metabolized statins like atorvastatin 6
- Dose-response exists: A 2024 Japanese study showed low cumulative doses (<30 days) paradoxically increased dementia risk (OR 1.42), while high cumulative doses (>180 days) were strongly protective (OR 0.33) 7
- Established dementia: One 2023 study found statins did not slow cognitive decline in those with existing mild-moderate Alzheimer's disease, though they remained safe 8—but this addresses progression, not prevention
The evidence strongly favors continuation of statin therapy in older adults, with dementia concerns representing an unfounded barrier to appropriate cardiovascular prevention that improves both mortality and quality of life.